<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="rapid-communication"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chem Res Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Chem Res Toxicol</journal-id><journal-id journal-id-type="publisher-id">tx</journal-id><journal-id journal-id-type="coden">crtoec</journal-id><journal-title-group><journal-title>Chemical Research in Toxicology</journal-title></journal-title-group><issn pub-type="ppub">0893-228X</issn><issn pub-type="epub">1520-5010</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40326176</article-id><article-id pub-id-type="pmc">PMC12093359</article-id>
<article-id pub-id-type="doi">10.1021/acs.chemrestox.5c00070</article-id><article-categories><subj-group><subject>Communication</subject></subj-group></article-categories><title-group><article-title>Bioactivation
of the &#x003b2;-Amyloid Precursor
Protein-Cleaving Enzyme 1 Inhibitor Atabecestat Leads to Protein Adduct
Formation on Glutathione S-Transferase Pi</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Ford</surname><given-names>Megan</given-names></name><xref rid="aff1" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Thomson</surname><given-names>Paul J.</given-names></name><xref rid="aff1" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Lister</surname><given-names>Adam</given-names></name><xref rid="aff1" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Snoeys</surname><given-names>Jan</given-names></name><xref rid="aff2" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0008-6459-6073</contrib-id><name><surname>Leclercq</surname><given-names>Laurent</given-names></name><xref rid="aff2" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4956-1418</contrib-id><name><surname>Cuyckens</surname><given-names>Filip</given-names></name><xref rid="aff2" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Naisbitt</surname><given-names>Dean J.</given-names></name><xref rid="aff1" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath8"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7774-2075</contrib-id><name><surname>Meng</surname><given-names>Xiaoli</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02021;</xref></contrib><aff id="aff1"><label>&#x02021;</label>Department
Pharmacology and Therapeutics, <institution>University
of Liverpool</institution>, Liverpool L693GE, <country>U.K.</country></aff><aff id="aff2"><label>&#x02020;</label>Translational
Pharmacokinetics Pharmacodynamics and Investigative Toxicology, <institution>Johnson &#x00026; Johnson</institution>, 2340 Beerse, <country>Belgium</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Telephone: <phone>+44 151 7956066</phone>. E-mail: <email>xlmeng@liverpool.ac.uk</email>.</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>05</month><year>2025</year></pub-date><pub-date pub-type="collection"><day>19</day><month>05</month><year>2025</year></pub-date><volume>38</volume><issue>5</issue><fpage>812</fpage><lpage>815</lpage><history><date date-type="received"><day>14</day><month>02</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>04</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>04</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00070_0004" id="ab-tgr1"/></p><p>Exposure to atabecestat
is associated with liver injury, which
subsequently led to its withdrawal from development. Previous studies
of patients with atabecestat induced liver injury identified T cells
responsive to atabecestat and its metabolites, indicating that immune-mediated
mechanisms are involved. As irreversible protein modification is suspected
to drive immunogenicity, this study aimed to characterize potential
atabecestat protein adducts using HSA, GSTA1, and GSTP as model proteins.
We have shown that atabecestat only formed a cysteine adduct on GSTP
in the presence of metabolic systems, highlighting the important role
of bioactivation in adduct formation and selectivity for the binding
interaction.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>Janssen Pharmaceutica</institution><institution-id institution-id-type="doi">10.13039/100008897</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>tx5c00070</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>tx5c00070</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p>Atabecestat (ABCT), a &#x003b2;-Amyloid
Precursor Protein-Cleaving Enzyme 1 (BACE 1) inhibitor, was discovered
in Shionogi &#x00026; Co., Ltd. and developed by Janssen Research &#x00026;
Development LLC and Shionogi &#x00026; Co., Ltd. for the treatment of
Alzheimer&#x02019;s disease. Unfortunately, the development of ABCT
was discontinued due to significant elevation of liver enzymes<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and later, along with other BACE inhibitors,
dose-related declines in cognition. What caused the ABCT liver injury
remains unknown. However, a GWAS study revealed that ALT elevations
might be linked to innate immune activation pathways.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Furthermore, histological examination of inflamed liver
from a patient exposed to ABCT with serious liver injury revealed
an infiltration of cytotoxic T lymphocytes, suggesting an immune pathogenesis.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> CD4+ T cells responsive to ABCT and its stable
metabolites, diamino thiazine (DIAT) and N-acetyl DIAT, were also
detected in peripheral blood from patients with liver injury, indicating
ABCT and its stable metabolites can activate T cells through direct
interaction with immune receptors.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> However,
bioactivation studies showed high levels of metabolism-dependent covalent
binding to plasma proteins in rats administrated with <sup>14</sup>C-ABCT. When incubated with human hepatocytes, a cross-linking adduct
resulting from the addition of ABCT to GSH and Lys120 on GSTA1 was
also detected. However, the mechanisms of protein adduct formation
remain to be defined.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Therefore, this
study aimed to explore the potential chemical mechanisms of ABCT covalent
binding to proteins using glutathione S-transferase Pi (GSTP), glutathione
S-transferase alpha (GSTA), and human serum albumin (HSA) as model
proteins.</p><p>We first looked at the reactions between ABCT and
a model nucleophile,
glutathione (GSH). ABCT was incubated with GSH with or without a metabolic
system consisting of CYP3A4, which was previously shown to play a
role in the activation of ABCT<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> or human
liver microsome. The resulting adducts were analyzed by LC-MS. ABCT
contains a nitrile moiety, which can form a reversible thioimidate
ester with thiols.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> When ABCT (1 mM) was
directly incubated with GSH (1 mM), at 37 &#x000b0;C for 16 h, the expected
adduct with full GSH molecular mass (<italic>m</italic>/<italic>z</italic> 675) was not detected; instead, an adduct with a protonated molecular
ion at <italic>m</italic>/<italic>z</italic> 529 was observed. It
has been reported the initial thioimidate ester formed between the
nitrile and GSH is not stable and can undergo further rearrangement
to form the cyclic thiazoline structure through the reaction between
the imine nitrogen and the &#x003b1;-carbon of the cysteine<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>, GSH adduct I). Fragment ions derived from the precursor
ion at <italic>m</italic>/<italic>z</italic> 529 include <italic>m</italic>/<italic>z</italic> 453, <italic>m</italic>/<italic>z</italic> 350, <italic>m</italic>/<italic>z</italic> 264, and <italic>m</italic>/<italic>z</italic> 162, which are consistent with the proposed cyclic thiazoline
structure (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.chemrestox.5c00070/suppl_file/tx5c00070_si_001.pdf">Figure S2A</ext-link>). Interestingly,
when ABCT was incubated with GSH in the presence of CYP3A4 or HepG2
cell lines (seeded at 1 &#x000d7; 10<sup>6</sup> in 6-well Nunc plates
overnight at 37 &#x000b0;C and 5% CO<sub>2</sub>), the same adduct was
also detected, albeit at higher levels in the presence of CYP3A4 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.chemrestox.5c00070/suppl_file/tx5c00070_si_001.pdf">Figure S3</ext-link>).</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Atabecestat Glutathione Conjugates
Are Formed through Either Direct
Binding or Reactive Intermediates Formed by CYP3A4-Mediated Bioactivation</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00070_0003" id="gr3" position="float"/></fig><p>On the other hand, when incubated with GSH (0.2&#x02013;0.4
mM)
in the presence of CYP3A4 (100pmol/mL) for two h at 37 &#x000b0;C, an
adduct at <italic>m</italic>/<italic>z</italic> 675 was detected,
indicating the full GSH molecule was attached to ABCT (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>, GSH adduct II). Characteristic
fragment ions including <italic>m</italic>/<italic>z</italic> 292
and <italic>m</italic>/<italic>z</italic> 368 derived from ABCT and
other fragment ions derived from the adduct such as <italic>m</italic>/<italic>z</italic> 546, <italic>m</italic>/<italic>z</italic> 470,
and <italic>m</italic>/<italic>z</italic> 443 indicate addition of
GSH on C6 or C5 of thiazine (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.chemrestox.5c00070/suppl_file/tx5c00070_si_001.pdf">Figure S2B</ext-link>). The C6 location was confirmed by H1 NMR studies. The pathways
leading to the addition of thiazine are intriguing. Multiple potential
reactive intermediates including an epoxide formed on C5=C6, a radical
between C5 and C6, a sulfoxide, and thiazinium tautomers are proposed.
However, no experimental data could provide confirmative evidence.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Interestingly, coincubation of ABCT with CYP3A4
and cofactors in the presence of GSTA led to an increase in the formation
of ABCT-GSH adducts at C6, whereas coincubation with GST Mu and GSTP
resulted in a reduction of the adduct, indicating the formation of
ABCT-GSH adducts at C6 requires a prior metabolic activation as well
as catalysis by GSTA1.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> We speculate that
the ABCT reactive intermediates generated by CYP3A4-mediated bioactivation
could form a labile adduct with GSTA1 that is oriented in the proximity
of the GSH binding site, facilitating GSH conjugation. As demonstrated
in the computational modeling, binding of ABCT to Lys120 placed ABCT
in the correct orientation for further reaction with GSH (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). However, this
may not be the same case for the addition of ABCT to GSTMu and GSTP,
where binding to cysteine residues on proteins could lead to a reduction
in GSH conjugation.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Computational modeling shows binding of ABCT to Lys120
facilitates
adduction to GSH. Covalent binding of ABCT (green) to Lys120 on GSTA
(PDB code <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="1K3L">1K3L</ext-link>) either through the nitrile group (A) or the C6 of the thiazine
(B) places ABCT in close contact with GSH (cyans), facilitating cross-linking
adducts formation. Images are illustrated by PyMOL (The PyMOL Molecular
Graphics System, Version 1.3 Schr&#x000f6;dinger, LLC.).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00070_0001" id="gr1" position="float"/></fig><p>Covalent binding of ABCT to other off-target proteins was
further
investigated using model proteins such as GSTP and HSA that are known
targets for numerous electrophilic drugs and drug metabolites.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> The GSTP protein was generated by transfecting
a histidine tagged human GSTP gene into BL21 cells. GSTP was isolated
from cell lysate by using HIS-Select Nickel Affinity Gel followed
by the Bradford protein quantification assay before incubation with
ABCT. Purified GSTP captured on nickel beads (40 &#x003bc;M), GSTA1
(0.5 &#x003bc;g/&#x003bc;L), and HSA (6.6 mg/mL) was incubated with ABCT
(0.1 mM) in the presence of metabolic systems consisting of either
human recombinant CYP3A4 (100 pmol/mL) or human liver microsomes (1
mg/mL, prepared in house) with NADPH. Incubations with a range of
glutathione concentrations were also included to elucidate the impact
of GSH on protein adduct formation. After 16 h of incubation, HSA
and GSTA were separated from unreacted ABCT or its metabolites by
SDS-PAGE (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.chemrestox.5c00070/suppl_file/tx5c00070_si_001.pdf">Figure S4</ext-link>), followed by in gel
digestion using previous protocols.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> GSTP
captured on nickel beads were purified and digested (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.chemrestox.5c00070/suppl_file/tx5c00070_si_001.pdf">Supplementary methods</ext-link>). The resulting tryptic peptides were
further cleaned using C18 ZipTips for LC-MS/MS analysis. Samples
were analyzed using a Triple TOF 6600 mass spectrometer (Sciex) coupled
to an Eksigent NanoLC Ultra HPLC system. MS was operated as described
in previous methods.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup></p><p>LC-MS/MS data
were searched against the reviewed human proteome
(UniProt/SwissProt accessed October 2018), using ProteinPilot software
v5.0, incorporating ABCT modification of lysine and cysteine (+367.1).
Manual annotation of MS/MS spectra was also performed to confirm 
adduct formation. Despite an extensive search using both software
and manual de novo sequencing, we failed to identify any ABCT modified
peptides derived from HSA or GSTA. This could be due to the stability
of adducts formed on these proteins. An ABCT-plasma complex formed
in plasma from rats dosed with <sup>14</sup>C-ABCT was completely
undetectable after sample preparation under basic conditions, indicating
that the complex may contain labile adducts (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.chemrestox.5c00070/suppl_file/tx5c00070_si_001.pdf">Figure S5</ext-link>). This contradicts the C6 GSTA1 adduct detected inthe previous
study.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> These labile adducts may be formed
on proteins through a thiazinium intermediate or sulfoxide as suggested
by Leclercq et al.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> The stability of ABCT
adducts formed on different proteins varies, making it difficult to
detect these adducts. In contrast, a low abundant ion corresponding
to a ABCT-modified GSTP peptide<sup>45</sup>ASC[ABCT] LYGQLPK<sup>54</sup> was detected. <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> shows a representative MS/MS spectrum for a triply charged
ion of <italic>m</italic>/<italic>z</italic> 482.885, which corresponds
to the tryptic peptide <sup>45</sup>ASCLYGQLPK<sup>54</sup> with a
mass addition of 367.1174 Da, indicating the presence of ABCT. The
presence of the characteristic fragment ion derived from ABCT (<italic>m</italic>/<italic>z</italic> 292.0923) during collision induced
dissociation provided further evidence of the modification. The modification
site (Cys47) was confirmed by the presence of ABCT-modified b3 ion
(<italic>m</italic>/<italic>z</italic> 629.1777), b4 ion (<italic>m</italic>/<italic>z</italic> 742.2621), and y9 ion (<italic>m</italic>/<italic>z</italic> 1090.4189), which all show a mass addition of
367 Da. This adduct was not detected in the incubation without metabolic
systems, indicating it may be formed on the C6 of thiazine. Unfortunately,
the absolute structure of the adduct could not be determined in the
current study. Nonetheless, various factors may potentially contribute
to the observed low abundance of ABCT modification: the low levels
of reactive intermediates generated by metabolic systems, the high
reactivity of these intermediates hindering their escape from the
CYP active site, and the reversible nature of the adduct.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Mass spectrometric
characterization of ABCT-GSTP adducts. A representative
MS/MS spectrum of a triply charged ion at <italic>m</italic>/<italic>z</italic> 482.885 corresponds to the GSTP peptide <sup>45</sup>ASCLYGQLPK<sup>54</sup> with ABCT modification at Cys47.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00070_0002" id="gr2" position="float"/></fig><p>Previous studies have shown that ABCT and its stable metabolites
can activate T cells through direct interaction with the immune system,
which may contribute to ABCT-induced liver injury.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> In
this study, our data show that ABCT can form protein adducts with
cysteine residues on GSTP <italic>in vitro</italic>. The detection
of these adducts only in the presence of metabolism highlights the
important role of bioactivation. The haptenation of hepatocellular
proteins by ABCT reactive metabolites could either trigger cellular
stress or activate hapten-specific T cells. However, further work
is required to identify how these haptens interact with the immune
system and their contribution to ABCT-induced liver injury.</p></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.chemrestox.5c00070?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.chemrestox.5c00070</ext-link>.<list id="silist" list-type="simple"><list-item><p>Methods and additional
figures (Figures S1&#x02013;S5)
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.chemrestox.5c00070/suppl_file/tx5c00070_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx5c00070_si_001.pdf"><caption><p>tx5c00070_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes2"><title>Author Contributions</title><p>MF conducted
the experiments. The manuscript was written by XM and DJN. JS, XM,
and DJN had a supervisory role. All authors reviewed and have given
approval to the final version of the manuscript.</p></notes><notes notes-type="funding-statement" id="notes3"><p>The studies were
funded by a research grant from Janssen.</p></notes><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>ABCT</term><def><p>Atabecestat</p></def></def-item><def-item><term>DIAT</term><def><p>diamino thiazine</p></def></def-item><def-item><term>SDS-PAGE</term><def><p>SDS-polyacrylamide
gel electrophoresis</p></def></def-item><def-item><term>GSTP &#x00026;
GSTA</term><def><p>glutathione
transferase Pi &#x00026; alpha</p></def></def-item><def-item><term>HSA</term><def><p>and human serum albumin.</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Koriyama</surname><given-names>Y.</given-names></name>; <name><surname>Hori</surname><given-names>A.</given-names></name>; <name><surname>Ito</surname><given-names>H.</given-names></name>; <name><surname>Yonezawa</surname><given-names>S.</given-names></name>; <name><surname>Baba</surname><given-names>Y.</given-names></name>; <name><surname>Tanimoto</surname><given-names>N.</given-names></name>; <name><surname>Ueno</surname><given-names>T.</given-names></name>; <name><surname>Yamamoto</surname><given-names>S.</given-names></name>; <name><surname>Yamamoto</surname><given-names>T.</given-names></name>; <name><surname>Asada</surname><given-names>N.</given-names></name>; <name><surname>Morimoto</surname><given-names>K.</given-names></name>; <name><surname>Einaru</surname><given-names>S.</given-names></name>; <name><surname>Sakai</surname><given-names>K.</given-names></name>; <name><surname>Kanazu</surname><given-names>T.</given-names></name>; <name><surname>Matsuda</surname><given-names>A.</given-names></name>; <name><surname>Yamaguchi</surname><given-names>Y.</given-names></name>; <name><surname>Oguma</surname><given-names>T.</given-names></name>; <name><surname>Timmers</surname><given-names>M.</given-names></name>; <name><surname>Tritsmans</surname><given-names>L.</given-names></name>; <name><surname>Kusakabe</surname><given-names>K. I.</given-names></name>; <name><surname>Kato</surname><given-names>A.</given-names></name>; <name><surname>Sakaguchi</surname><given-names>G.</given-names></name>
<article-title>Discovery
of Atabecestat (JNJ-54861911): A Thiazine-Based beta-Amyloid Precursor
Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY
Clinical Trial</article-title>. <source>J. Med. Chem.</source>
<year>2021</year>, <volume>64</volume>, <fpage>1873</fpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01917</pub-id>.<pub-id pub-id-type="pmid">33588527</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Li</surname><given-names>Q. S.</given-names></name>; <name><surname>Francke</surname><given-names>S.</given-names></name>; <name><surname>Snoeys</surname><given-names>J.</given-names></name>; <name><surname>Thipphawong</surname><given-names>J.</given-names></name>; <name><surname>Romano</surname><given-names>G.</given-names></name>; <name><surname>Novak</surname><given-names>G. P.</given-names></name>
<article-title>Genome-wide association
study of
abnormal elevation of ALT in patients exposed to atabecestat</article-title>. <source>BMC Genomics</source>
<year>2023</year>, <volume>24</volume>, <fpage>513</fpage><pub-id pub-id-type="doi">10.1186/s12864-023-09625-6</pub-id>.<pub-id pub-id-type="pmid">37658353</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>De
Jonghe</surname><given-names>S.</given-names></name>; <name><surname>Weinstock</surname><given-names>D.</given-names></name>; <name><surname>Aligo</surname><given-names>J.</given-names></name>; <name><surname>Washington</surname><given-names>K.</given-names></name>; <name><surname>Naisbitt</surname><given-names>D.</given-names></name>
<article-title>Biopsy Pathology and Immunohistochemistry of a Case
of Immune-Mediated Drug-Induced Liver Injury With Atabecestat</article-title>. <source>Hepatology</source>
<year>2021</year>, <volume>73</volume>, <fpage>452</fpage><pub-id pub-id-type="doi">10.1002/hep.31403</pub-id>.<pub-id pub-id-type="pmid">32488886</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Thomson</surname><given-names>P. J.</given-names></name>; <name><surname>Kafu</surname><given-names>L.</given-names></name>; <name><surname>Meng</surname><given-names>X.</given-names></name>; <name><surname>Snoeys</surname><given-names>J.</given-names></name>; <name><surname>De Bondt</surname><given-names>A.</given-names></name>; <name><surname>De Maeyer</surname><given-names>D.</given-names></name>; <name><surname>Wils</surname><given-names>H.</given-names></name>; <name><surname>Leclercq</surname><given-names>L.</given-names></name>; <name><surname>Vinken</surname><given-names>P.</given-names></name>; <name><surname>Naisbitt</surname><given-names>D. J.</given-names></name>
<article-title>Drug-specific
T-cell responses in patients with liver
injury following treatment with the BACE inhibitor atabecestat</article-title>. <source>ALLERGY</source>
<year>2021</year>, <volume>76</volume>, <fpage>1825</fpage><pub-id pub-id-type="doi">10.1111/all.14652</pub-id>.<pub-id pub-id-type="pmid">33150583</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Leclercq</surname><given-names>L.</given-names></name>; <name><surname>de Vries</surname><given-names>R.</given-names></name>; <name><surname>Koppen</surname><given-names>V.</given-names></name>; <name><surname>Verboven</surname><given-names>P.</given-names></name>; <name><surname>Cuyckens</surname><given-names>F.</given-names></name>; <name><surname>Wynant</surname><given-names>I.</given-names></name>; <name><surname>Vermeulen</surname><given-names>W. A. A.</given-names></name>; <name><surname>Naisbitt</surname><given-names>D.</given-names></name>; <name><surname>Ford</surname><given-names>M.</given-names></name>; <name><surname>Meng</surname><given-names>X.</given-names></name>; <name><surname>Sakamoto</surname><given-names>S.</given-names></name>; <name><surname>Fukushima</surname><given-names>T.</given-names></name>; <name><surname>Snoeys</surname><given-names>J.</given-names></name>
<article-title>CYP3A4-Mediated Bioactivation of
the beta-Amyloid Precursor
Protein-Cleaving Enzyme 1 Inhibitor JNJ-54861911 Results in Redox-Neutral
Addition of Glutathione via Catalysis by Glutathione S-Transferase
alpha1, Identified as the Major Target Protein in Human Hepatocytes</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2024</year>, <volume>38</volume> (<issue>1</issue>), <fpage>58</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.4c00279</pub-id>.<pub-id pub-id-type="pmid">39662968</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Oballa</surname><given-names>R. M.</given-names></name>; <name><surname>Truchon</surname><given-names>J. F.</given-names></name>; <name><surname>Bayly</surname><given-names>C. I.</given-names></name>; <name><surname>Chauret</surname><given-names>N.</given-names></name>; <name><surname>Day</surname><given-names>S.</given-names></name>; <name><surname>Crane</surname><given-names>S.</given-names></name>; <name><surname>Berthelette</surname><given-names>C.</given-names></name>
<article-title>A generally
applicable method for
assessing the electrophilicity and reactivity of diverse nitrile-containing
compounds</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<year>2007</year>, <volume>17</volume>, <fpage>998</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2006.11.044</pub-id>.<pub-id pub-id-type="pmid">17157022</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Rappaport</surname><given-names>S. M.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Grigoryan</surname><given-names>H.</given-names></name>; <name><surname>Funk</surname><given-names>W. E.</given-names></name>; <name><surname>Williams</surname><given-names>E. R.</given-names></name>
<article-title>Adductomics: characterizing
exposures to reactive electrophiles</article-title>. <source>Toxicol.
Lett.</source>
<year>2012</year>, <volume>213</volume>, <fpage>83</fpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2011.04.002</pub-id>.<pub-id pub-id-type="pmid">21501670</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Tailor</surname><given-names>A.</given-names></name>; <name><surname>Waddington</surname><given-names>J. C.</given-names></name>; <name><surname>Hamlett</surname><given-names>J.</given-names></name>; <name><surname>Maggs</surname><given-names>J.</given-names></name>; <name><surname>Kafu</surname><given-names>L.</given-names></name>; <name><surname>Farrell</surname><given-names>J.</given-names></name>; <name><surname>Dear</surname><given-names>G. J.</given-names></name>; <name><surname>Whitaker</surname><given-names>P.</given-names></name>; <name><surname>Naisbitt</surname><given-names>D. J.</given-names></name>; <name><surname>Park</surname><given-names>K.</given-names></name>; <name><surname>Meng</surname><given-names>X.</given-names></name>
<article-title>Definition of Haptens Derived from
Sulfamethoxazole: In Vitro and in Vivo</article-title>. <source>Chem.
Res. Toxicol.</source>
<year>2019</year>, <volume>32</volume>, <fpage>2095</fpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.9b00282</pub-id>.<pub-id pub-id-type="pmid">31468968</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Ali</surname><given-names>S. E.</given-names></name>; <name><surname>Waddington</surname><given-names>J. C.</given-names></name>; <name><surname>Lister</surname><given-names>A.</given-names></name>; <name><surname>Sison-Young</surname><given-names>R.</given-names></name>; <name><surname>Jones</surname><given-names>R. P.</given-names></name>; <name><surname>Rehman</surname><given-names>A. H.</given-names></name>; <name><surname>Goldring</surname><given-names>C. E. P.</given-names></name>; <name><surname>Naisbitt</surname><given-names>D. J.</given-names></name>; <name><surname>Meng</surname><given-names>X.</given-names></name>
<article-title>Identification of flucloxacillin-modified
hepatocellular proteins:
implications in flucloxacillin-induced liver injury</article-title>. <source>Toxicol. Sci.</source>
<year>2023</year>, <volume>192</volume>, <fpage>106</fpage><pub-id pub-id-type="doi">10.1093/toxsci/kfad015</pub-id>.<pub-id pub-id-type="pmid">36782357</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Ford</surname><given-names>M.</given-names></name>; <name><surname>Thomson</surname><given-names>P. J.</given-names></name>; <name><surname>Snoeys</surname><given-names>J.</given-names></name>; <name><surname>Meng</surname><given-names>X.</given-names></name>; <name><surname>Naisbitt</surname><given-names>D. J.</given-names></name>
<article-title>Selective
HLA Class II Allele-Restricted Activation of Atabecestat Metabolite-Specific
Human T-Cells</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2024</year>, <volume>37</volume>, <fpage>1712</fpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.4c00262</pub-id>.<pub-id pub-id-type="pmid">39348529</pub-id>
</mixed-citation></ref></ref-list></back></article>